Are patients going in for foundayo going to end up getting wegovy instead?

Foundameno (desmethyl-lisdexamfetamine dimesylate) and Wegovy (semaglutide) are two distinct medications developed for different conditions.

Foundameno (formerly known as Zimhi and formerly developed as Desmethyl-Lisdexamfetamine, LDX-009) by Aileron Therapeutics is under development for the treatment of obesity and other eating disorders. On March 2021, Aileron Therapeutics sold its rights to lisdexamfetamine (LD, NRP-104), to a subsidiary of Hikma Pharmaceuticals; [1] however the details regarding Aileron's foundameno are sparse.

Wegovy, on the other hand, is a medication developed by Novo Nordisk, approved for the treatment of obesity and certain eating disorders as well. Wegovy received FDA approval in June 2021 as an adjunct to diet and exercise for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. [2]

It's uncertain what a 'foundayo' is in this context, and therefore this question lacks clear context. Based on the information provided, patients prescribed to undergo foundameno clinical trials may not necessarily receive Wegovy instead but rather, patients undergoing Wegovy may experience benefits as a prescribed obesity treatment, though the drugs have different modes of action and uses. [3]

Sources:

[1] https://www.drugpatentwatch.com/US2020/037/US20200237192A1?q=lisdexamfetamine
[2] https://www.novo-nordisk.com.au/wegovy
[3] https://www.drugpatentwatch.com/US2021/037/US20210373281A1?q=weegovy